| Patient | John Locke |
|---|---|
| Date of birth | 1966-09-08 |
| Identifiers | MRN HR-EN001-SYN; SSN (made up) 000-01-8305 |
| Document date | 2026-06-18 |
| Author | Prudence Hartwell-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twelve-week asthma review with repeat spirometry. [S]
Mr. Locke returns twelve weeks after starting budesonide-formoterol as maintenance and reliever. He finished the eight-week pulmonary rehabilitation program, attending all 16 sessions, and walks 30 minutes five days a week. He needs three or four extra inhalations a week, mostly after his days in the city, and woke at night with cough once in the past month. He has had no flare and no oral corticosteroids. The dose counter matches his diary, with about one missed evening dose a fortnight. He has had no hoarseness or sore mouth. His home peak flow is best at 440 L/min in the mornings and falls to about 360 after a city day. The open fires stay out; a small air monitor in his study usually reads below 10 ug/m3 of PM2.5. He has spent two or three days a month in the city and stayed away during an air quality alert in May. [S]
| Element | Detail |
|---|---|
| Reliever use | Three or four extra inhalations a week |
| Night waking | Once in the past month |
| Adherence | About one missed maintenance dose a fortnight; dose counter agrees |
| Rehabilitation | 16 of 16 sessions completed |
| Peak flow | Personal best 440 L/min |
| Asthma Control Test | 19, up from 13 |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless on steep hills; some cough and tightness after city days; no hemoptysis |
| Ears, nose, mouth, and throat | Negative | No hoarseness, sore mouth, or thrush |
| Cardiovascular | Negative | No palpitations, tremor, or ankle swelling |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometry | Two puffs every 4 hours as needed | Respiratory tract route | 2026-03-12 to 2026-03-26 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | Two inhalations twice daily plus one as needed; no more than 12 a day | Respiratory tract route | 2026-03-26 | active | S |
| Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5) | Two inhalations once a day | Respiratory tract route | 2026-06-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-18 | Body height | 178 | cm | S |
| 2026-06-18 | Body weight | 62.8 | kg | S |
| 2026-06-18 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-06-18 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-06-18 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-06-18 | Heart rate | 76 | /min | S |
| 2026-06-18 | Respiratory rate | 16 | /min | S |
| 2026-06-18 | Body temperature | 36.6 | Cel | S |
| 2026-06-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-18 | Total score [ACT] | 19 | {score} | S | ||
| 2026-06-18 | FEV1 --pre bronchodilation | 2.46 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 2026-06-18 | FEV1 measured/predicted | 73 | % | GLI Global race-neutral equations for a man of 59, 178 cm | Low | S |
| 2026-06-18 | FEV1 --post bronchodilation | 2.58 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 2026-06-18 | Forced vital capacity [Volume] Respiratory system --post bronchodilation | 4.12 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 L | Normal | S |
| 2026-06-18 | FEV1/FVC --post bronchodilation | 0.63 | {ratio} | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitation | Low | S |
| 2026-06-18 | Fractional concentration of exhaled nitric oxide | 22 | [ppb] | In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS) | Normal | S |
| 2026-06-18 | Six minute walk test | 505 | m | Predicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 m | Normal | S |
Vital signs recorded on 2026-06-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 62.8 kg |
| Mouth | No oral candidiasis |
| Respiratory | Good air entry; a few end-expiratory wheezes on forced expiration; oxygen saturation 97 percent |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluation | resolved | confirmed | R05.3 | S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit. |
| Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at home | active | confirmed | Z77.110 | S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted. |
| Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPD | active | confirmed | J45.40 | S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 19, up from 13; not yet well controlled (20 or more) |
| Imaging | Spirometry before and after bronchodilator | At diagnosis, 3 to 6 months after starting treatment, then every 1 to 2 years | Completed today | FEV1 2.46 L before (73 percent predicted) and 2.58 L after bronchodilator; FVC 4.12 L after; FEV1/FVC 0.63 after, still below the lower limit of normal; next in one to two years |
| Imaging | FeNO | To monitor inhaled-corticosteroid response | Completed today | 22 ppb, down from 41 |
| Imaging | Six-minute walk test | Before and after pulmonary rehabilitation | Completed today | 505 m, up 75 m from 430 m |
| Imaging | Home peak expiratory flow | Daily for moderate to severe asthma, then with symptoms | Completed today | Diary reviewed: personal best 440 L/min; about 360 after city days |
| Examination | Inhaler technique with his own devices | Every visit | Completed today | Budesonide-formoterol technique correct; tiotropium soft-mist inhaler taught today, correct by teach-back |
| Medication safety | Adherence and reliever use | Every visit | Completed today | About one missed maintenance dose a fortnight by dose counter and diary; three or four as-needed inhalations a week |
| Medication safety | Inhaled-corticosteroid side effects (hoarseness, thrush) | Every visit | Completed today | None |
| Survey | Exacerbation history | Every visit | Completed today | None since treatment began; no oral corticosteroids |
| Self-management | Trigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergens | Every visit | Completed today | Open fires out of use; indoor PM2.5 on his monitor usually below 10 ug/m3; HEPA air cleaners running; city trip postponed during an air quality alert |
| Self-management | Smoking and vaping status | Every visit | Completed today | Never smoker; no vaping; no secondhand smoke |
| Self-management | Written asthma action plan | Every visit and after every flare | Completed today | Updated with peak-flow zones: green 352 or more, yellow 220 to 351, red below 220 L/min |
| Medication safety | Step-up and step-down assessment | Every visit | Completed today | Not well controlled on step 4 with good adherence and technique: step up by adding tiotropium (step 5) |
| Referral | Pulmonary rehabilitation | For persistent breathlessness or reduced exercise capacity | Completed today | Program completed; home walking program to maintain the gain |
| Self-management | Vaccination status | Yearly | Up to date | PCV20 given at the diagnosis visit; influenza, COVID-19, and RSV vaccines due in the autumn |
| Medication safety | Biologic candidacy | When asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and technique | Not indicated | No exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Preventive visit in three months, with a brief asthma check; asthma review with an Asthma Control Test in four months. Next scheduled visit 2026-09-17: preventive health visit at 60. [S]